The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 327.00
Bid: 328.50
Ask: 330.50
Change: -7.50 (-2.24%)
Spread: 2.00 (0.609%)
Open: 329.00
High: 332.50
Low: 321.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

Fri, 22nd Sep 2023 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

----------

FTSE 100

----------

UBS raises Next price target to 7,250 (6,850) pence - 'neutral'

----------

SocGen raises Next price target to 8,287 (8,239) pence - 'buy'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

JPMorgan raises Next price target to 7,500 (7,300) pence - 'neutral'

----------

Goldman Sachs cuts SSE price target to 2,390 (2,431) pence - 'buy'

----------

JPMorgan raises M&G price target to 195 (180) pence - 'underweight'

----------

JPMorgan raises Admiral Group price target to 1,700 (1,650) pence - 'underweight'

----------

JPMorgan cuts Phoenix Group to 'underweight' (neutral) - price target 500 (655) pence

----------

JPMorgan cuts Prudential price target to 1,500 (1,630) pence - 'overweight'

----------

JPMorgan cuts Legal & General price target to 290 (315) pence - 'overweight'

----------

RBC raises Hargreaves Lansdown target to 900 (875) pence - 'sector perform'

----------

Deutsche Bank cuts Lloyds Banking price target to 62 (63) pence - 'buy'

----------

Deutsche Bank cuts Barclays price target to 200 (230) pence - 'hold'

----------

Deutsche Bank cuts NatWest price target to 320 (370) pence - 'buy'

----------

JPMorgan raises BP price target to 600 (530) pence - 'neutral'

----------

JPMorgan raises Shell price target to 3,200 (2,750) pence - 'overweight'

----------

FTSE 250

----------

Bank of America starts Dowlais with 'buy' - price target 144 pence

----------

Jefferies cuts Victrex price target to 1,420 (1,590) pence - 'hold'

----------

JPMorgan raises Hiscox to 'overweight' (neutral) - price target 1,300 (1,200) pence

----------

JPMorgan raises Just Group price target to 125 (120) pence - 'overweight'

----------

JPMorgan cuts Lancashire to 'neutral' (overweight) - price target 715 (750) pence

----------

Berenberg cuts Mobico Group price target to 140 (220) pence - 'buy'

----------

Deutsche Bank cuts Dunelm price target to 1,310 (1,340) pence - 'buy'

----------

Deutsche Bank cuts Virgin Money UK target to 210 (220) pence - 'hold'

----------

SMALL CAP

----------

Berenberg raises DFS Furniture price target to 185 (155) pence - 'buy'

----------

JPMorgan cuts Oxford BioMedica price target to 325 (495) pence - 'neutral'

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 May 2020 12:52

Oxford Biomedica swings to loss as licensing revenue falls

(Sharecast News) - Gene and cell therapy company Oxford Biomedica reported an improvement in bioprocessing and commercial development revenues to ?47.3m in its preliminary results on Wednesday, from ?40.5m.

Read more
29 Apr 2020 16:13

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
28 Apr 2020 11:13

Liberum hikes target price on Oxford Biomedica

(Sharecast News) - Analysts at Liberum hiked their target price on gene and cell therapy company Oxford BioMedica from £8.60 per share to £10.90 on Tuesday, citing demand at its new OxBox manufacturing facility.

Read more
8 Apr 2020 16:13

Oxford Biomedica joins Covid-19 vaccine consortium

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.

Read more
8 Apr 2020 14:46

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

Read more
20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

Read more
19 Mar 2020 10:59

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Read more
4 Feb 2020 12:10

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Read more
19 Dec 2019 16:27

Oxford Biomedica Extends Agreement With Novartis By Five Years

Oxford Biomedica Extends Agreement With Novartis By Five Years

Read more
30 Sep 2019 09:55

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

Read more
28 May 2019 13:18

Novo Holdings pours ?53.5m into Oxford Biomedica

(Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to £53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.

Read more
15 Mar 2019 12:46

Friday broker round-up

(Sharecast News) - Bakkavor Group: Berenberg downgrades to sell with a target price of 105p.

Read more
14 Mar 2019 14:16

Oxford Biomedica swings to positive earnings in 2018

(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to £67.9m.

Read more
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.